Safety and Efficacy Study of AVB-S6-500 in Patients With Advanced Pancreatic Adenocarcinoma
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1b/2 study of AVB-S6-500 designed to evaluate the safety and efficacy of
AVB-S6-500 in combination with nab-paclitaxel and gemcitabine in subjects with locally
advanced, recurrent, or metastatic pancreatic adenocarcinoma as first line therapy. The phase
1b portion of the study is open label and patients will receive AVB-S6-500, nab-paclitaxel,
and gemcitabine. The Phase 2 portion of the study is randomized, 2-arm, open-label study to
compare efficacy and tolerability of AVB-S6-500, nab-paclitaxel, and gemcitabine versus
nab-paclitaxel and gemcitabine as first line therapy.